A retrospective analysis of the LiGHT Trial reported selective laser trabeculoplasty (SLT) as a first-line glaucoma treatment achieved a 29% slower visual field (VF) progression rate compared to medication after six years. 

Dr Giovanni Montesano, first author of the UK research, clinical glaucoma fellow at Moorfields Eye Hospital and member of the LiGHT Trial Study Group, said their statistical method separates the underlying distribution of ‘true’ VF progression rates from perimetric noise and learning. “These results confirm previous evidence from the LiGHT trial with a more robust statistical methodology and a longer follow-up. This is particularly important to improve generalisability of the results when analysing data from newly diagnosed patients who are likely naïve to VF testing,” he said.